JPH11512437A - S−ニトロソチオールを負荷した赤血球およびその使用 - Google Patents
S−ニトロソチオールを負荷した赤血球およびその使用Info
- Publication number
- JPH11512437A JPH11512437A JP9512111A JP51211197A JPH11512437A JP H11512437 A JPH11512437 A JP H11512437A JP 9512111 A JP9512111 A JP 9512111A JP 51211197 A JP51211197 A JP 51211197A JP H11512437 A JPH11512437 A JP H11512437A
- Authority
- JP
- Japan
- Prior art keywords
- sno
- red blood
- erythrocytes
- blood cells
- feii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/631—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited using photolysis and investigating photolysed fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plasma & Fusion (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.低分子量のニトロソ化剤の溶液中で赤血球をインキュベートする工程を含む 、単離された赤血球を低分子量のニトロソ化剤で負荷する方法。 2.低分子量のニトロソ化剤がS−ニトロソシステイン、S−ニトロソホモシス テインおよびS−ニトロソシステイニルグリシンからなる群より選ばれる請求項 1記載の単離された赤血球の負荷方法。 3.下記工程: a)哺乳動物から赤血球を取り出す工程; b)該赤血球を低分子量のニトロソ化剤の溶液中でインキュベートする工程;お よび c)該赤血球を該哺乳動物に再導入する工程 を含む、哺乳動物細胞へのNOの送達方法。 4.下記工程: a)哺乳動物から赤血球を取り出す工程; b)該赤血球を低分子量のニトロソ化剤の溶液中でインキュベートする工程;お よび c)該赤血球を該哺乳動物に再導入する工程 を含む、哺乳動物の赤血球のO2送達能を高める方法。 5.下記工程: a)哺乳動物から赤血球を取り出す工程; b)該赤血球を低分子量のニトロソ化剤の溶液中でインキュベートする工程;お よび c)該赤血球を該哺乳動物に再導入する工程 を含む、哺乳動物における酸素フリーラジカルの捕捉方法。 6.S−ニトロソ化ヘモグロビンを含むようにニトロソ化剤で処理された赤血球 の懸濁液中で器官をインキュベートする工程を含む、生きた器官の保存方法。 7.下記工程: a)哺乳動物の赤血球を単離する工程; b)該哺乳動物の赤血球をニトロソ化剤で処理する工程;および c)該哺乳動物に該赤血球を再投与する工程 を含む、哺乳動物における疾患または医学的障害の治療方法。 8.該疾患または医学的障害がショック、アンギナ、発作、再潅流損傷、急性肺 損傷、鎌状赤血球貧血および赤血球の感染からなる群より選ばれる請求項7記載 の方法。 9.該疾患が鎌状赤血球貧血であり、該ニトロソ化剤がS−ニトロソシステイン である請求項7記載の方法。 10.低分子量のニトロソ化剤で負荷されてなる赤血球。 11.負荷された赤血球を哺乳動物に投与する工程を含む、哺乳動物において血 圧を低下させる方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US380195P | 1995-09-15 | 1995-09-15 | |
US60/003,801 | 1995-09-15 | ||
US08/616,255 US6153186A (en) | 1995-09-15 | 1996-03-15 | Red blood cells loaded with S-nitrosothiol and uses therefor |
US08/616,255 | 1996-03-15 | ||
PCT/US1996/014664 WO1997009972A1 (en) | 1995-09-15 | 1996-09-13 | Erythrocytes loaded with s-nitrosothiol and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512437A true JPH11512437A (ja) | 1999-10-26 |
JP4262308B2 JP4262308B2 (ja) | 2009-05-13 |
Family
ID=26672210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51211197A Expired - Fee Related JP4262308B2 (ja) | 1995-09-15 | 1996-09-13 | S−ニトロソチオールを負荷した赤血球およびその使用 |
Country Status (8)
Country | Link |
---|---|
US (3) | US6153186A (ja) |
EP (1) | EP0850053B1 (ja) |
JP (1) | JP4262308B2 (ja) |
AT (1) | ATE421319T1 (ja) |
AU (1) | AU715651B2 (ja) |
CA (1) | CA2231916C (ja) |
DE (1) | DE69637825D1 (ja) |
WO (1) | WO1997009972A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627738B2 (en) * | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6916471B2 (en) * | 1995-09-15 | 2005-07-12 | Duke University | Red blood cells loaded with S-nitrosothiol and uses therefor |
US7179615B1 (en) * | 1997-07-29 | 2007-02-20 | Menzies School Of Health Research | Method of prophylaxis and treatment |
FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
ATE456056T1 (de) * | 1999-08-02 | 2010-02-15 | Univ Duke | Methode zur bestimmung der physiologischen wirkungen von hämoglobin |
US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
US6946484B2 (en) | 2000-04-26 | 2005-09-20 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20030228564A1 (en) * | 2001-05-30 | 2003-12-11 | Edrich Richard Alan | Nitric oxide in a pathogen inactivation process |
CA2487719A1 (en) * | 2002-05-29 | 2003-12-11 | Duke University | Measuring nitric oxide in blood gases and treatments based thereon |
WO2004054433A2 (en) * | 2002-12-12 | 2004-07-01 | Duke University | Forming iron nitrosyl hemoglobin |
DE602004008927T2 (de) | 2003-07-09 | 2008-06-05 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen |
US7744928B2 (en) * | 2006-04-14 | 2010-06-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treatment of lesioned sites of body vessels |
AU2008345034A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
WO2011031289A1 (en) * | 2009-09-08 | 2011-03-17 | Duke University | Novel medical uses for no and no donor compounds |
WO2015054378A1 (en) * | 2013-10-08 | 2015-04-16 | Drexel University | Novel microfluidic devices for diagnosing red blood cells abnormalities, and methods using same |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4900719A (en) * | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
DE69233491T2 (de) * | 1991-11-14 | 2006-04-06 | The Brigham And Women's Hospital Inc., Boston | Pharmazeutische Zusammensetzung enthaltend S-Nitrosolipoproteine und deren Verwendung |
WO1993012068A1 (en) * | 1991-12-11 | 1993-06-24 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
US5296466A (en) * | 1992-02-19 | 1994-03-22 | Board Of Regents, The University Of Texas System | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
US5632981A (en) * | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5405919A (en) * | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5482945A (en) * | 1992-12-22 | 1996-01-09 | American Home Products Corporation | Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements |
US5457024A (en) * | 1993-01-22 | 1995-10-10 | Aprogenex, Inc. | Isolation of fetal erythrocytes |
WO1994022482A1 (en) * | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
AU6528494A (en) * | 1993-04-06 | 1994-10-24 | Brigham And Women's Hospital | Nitric oxide combination therapy |
US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
US5547861A (en) * | 1994-04-18 | 1996-08-20 | Becton, Dickinson And Company | Detection of nucleic acid amplification |
GB9423868D0 (en) * | 1994-11-25 | 1995-01-11 | Wellcome Found | Compounds for use in medicine |
GB9424694D0 (en) * | 1994-12-07 | 1995-02-01 | Wellcome Found | Compounds for use in medicine |
AU5368296A (en) * | 1995-03-24 | 1996-10-16 | Brigham And Women's Hospital | Nitrosylated blood substitutes |
US6627738B2 (en) * | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6197745B1 (en) * | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
-
1996
- 1996-03-15 US US08/616,255 patent/US6153186A/en not_active Expired - Lifetime
- 1996-09-13 JP JP51211197A patent/JP4262308B2/ja not_active Expired - Fee Related
- 1996-09-13 CA CA2231916A patent/CA2231916C/en not_active Expired - Fee Related
- 1996-09-13 WO PCT/US1996/014664 patent/WO1997009972A1/en active Application Filing
- 1996-09-13 AT AT96931551T patent/ATE421319T1/de not_active IP Right Cessation
- 1996-09-13 AU AU70199/96A patent/AU715651B2/en not_active Expired
- 1996-09-13 DE DE69637825T patent/DE69637825D1/de not_active Expired - Fee Related
- 1996-09-13 EP EP96931551A patent/EP0850053B1/en not_active Expired - Lifetime
-
1997
- 1997-06-12 US US08/873,679 patent/US6203789B1/en not_active Expired - Lifetime
-
2008
- 2008-02-05 US US12/012,791 patent/US20080220095A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU715651B2 (en) | 2000-02-10 |
JP4262308B2 (ja) | 2009-05-13 |
US6153186A (en) | 2000-11-28 |
US20080220095A1 (en) | 2008-09-11 |
ATE421319T1 (de) | 2009-02-15 |
AU7019996A (en) | 1997-04-01 |
WO1997009972A1 (en) | 1997-03-20 |
US6203789B1 (en) | 2001-03-20 |
DE69637825D1 (de) | 2009-03-12 |
CA2231916C (en) | 2011-01-04 |
EP0850053B1 (en) | 2009-01-21 |
EP0850053A1 (en) | 1998-07-01 |
CA2231916A1 (en) | 1997-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7538193B2 (en) | NO-modified hemoglobins and uses therefor | |
JPH11512437A (ja) | S−ニトロソチオールを負荷した赤血球およびその使用 | |
AU720729B2 (en) | Nitrosated hemoglobins and therapeutic uses therefor | |
JP3628019B2 (ja) | ニトロキシドを用いる酸素毒性の防止用組成物と防止法 | |
US20090232909A1 (en) | Method for determining physiological effects of hemoglobin | |
EP1015490B1 (en) | No-modified hemoglobins and uses therefor | |
WO1998034955A9 (en) | No-modified hemoglobins and uses therefor | |
US7329543B2 (en) | Red blood cells loaded with S-nitrosothiol and uses therefor | |
FR2522269A1 (fr) | Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux | |
US6911427B1 (en) | No-modified hemoglobins and uses therefore | |
US6855691B1 (en) | Methods for producing and using S-nitrosohemoglobins | |
WO1997018000A1 (en) | S-nitroso-hemoglobin and therapeutic uses thereof | |
WO2018089756A1 (en) | Targeted anticoagulant | |
FR2575160A1 (fr) | Composes ionophores carboxyliques monovalents | |
FR2564839A1 (fr) | Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080905 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20081106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090113 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090209 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140220 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |